InMed (INM) 10% Owner Vivo Opportunity LLC Buys Shares

What Happened
Vivo Opportunity, LLC (reported as a 10% owner/related general partner) made multiple open-market purchases of InMed Pharmaceuticals (INM) common stock between June 30 and July 2, 2026. The filing shows a total of 6,551 shares acquired for an aggregate reported value of about $10,148. Individual entries include purchases at reported prices of $1.54 and $1.55 (weighted-average reporting; see footnotes for price ranges). These were purchases (buying shares), which investors typically view as accumulation rather than disposition.

Key Details

• Transaction dates and reported amounts:
  • 2026-06-30: 545 shares @ $1.54 ($839) and 55 shares @ $1.54 ($85)
  • 2026-07-01: 3,946 shares @ $1.55 ($6,116) and 398 shares @ $1.55 ($617)
  • 2026-07-02: 1,460 shares @ $1.55 ($2,263) and 147 shares @ $1.55 ($228)
• Total acquired: 6,551 shares for ~$10,148.
• Shares owned after the transactions: Not disclosed in the provided filing.
• Notable footnotes:
  • Vivo Opportunity, LLC (and related Cayman entity) is noted as general partner of record holders and disclaims beneficial ownership except to the extent of pecuniary interest (F1, F2) — this is institutional/partner reporting, not an individual executive.
  • Reported prices are weighted averages; underlying trades occurred across price ranges roughly $1.51–$1.60 (see F3–F5). The filer can provide breakdowns on request.
• Timeliness: Filing date 2026-07-02 for trades through 2026-07-02; no late-filing flag indicated in the provided data.

Context
This report covers open-market purchases by an institutional/affiliate entity (a 10% owner’s general partner). Such buys indicate that the investor increased its stake modestly, but the filing’s disclaimers mean the reporting entity limits its claimed beneficial ownership. Because this is institutional accumulation rather than an insider executive trade, interpret it as an ownership change by a fund-related party rather than a management sentiment signal.